Protocol Ledger

NCT06585787 · Phase III · RECRUITING

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Interventional Phase III clinical trial protocol NCT06585787 sponsored by Bristol Myers Squibb in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-26 Enrollment: 406 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06585787
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)406 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06585787
Protocol FieldVerified Registry Value
NCT IdentifierNCT06585787
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment406 participants (ESTIMATED)
Registered Start Date2024-09-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06585787
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI